Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PET tracer starts phase I trial:

This article was originally published in Clinica

Executive Summary

FluoroPharma is to begin phase I clinical trials of its imaging agent BFPET, following US institutional review board approval of the proposed studies. The planned trial will evaluate safety, distribution, and dosimetry of BFPET as a positron emission tomography (PET) blood flow tracer for myocardial perfusion imaging in healthy subjects. More than nine million patients undergo myocardial perfusion imaging - the standard test to assess coronary artery disease - annually in the US. Boston, Massachusetts-based FluoroPharma is a subsidiary of QuantRx.

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT046617

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel